about
Genes, tolerance and systemic autoimmunityMetabolism Is Central to Tolerogenic Dendritic Cell FunctionTolerogenic Dendritic Cells for Regulatory T Cell Induction in ManA tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessationCostimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis CRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Targeting dendritic cell function during systemic autoimmunity to restore toleranceNivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceContribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosusTargeted immune therapy of ovarian cancerPD-L1 regulates the development, maintenance, and function of induced regulatory T cellsInhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1Dendritic cells in chronic mycobacterial granulomas restrict local anti-bacterial T cell response in a murine model.Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus riskCNS expression of B7-H1 regulates pro-inflammatory cytokine production and alters severity of Theiler's virus-induced demyelinating disease.Dendritic cell-based human immunodeficiency virus vaccine.CD8+ Tregs in lupus, autoimmunity, and beyond.T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infectionTargeting inhibitory pathways in cancer immunotherapy.Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice.Up-regulation of Th17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells.PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitisPD-1 regulates extrathymic regulatory T-cell differentiation.Tumor antigen cross-presentation and the dendritic cell: where it all begins?DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-γ producing T cells.Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic optionsHuman placenta-derived adherent cells induce tolerogenic immune responsesDendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway.PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.How tolerogenic dendritic cells induce regulatory T cellsT-cell growth, cell surface organization, and the galectin-glycoprotein lattice.FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia.Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation.Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancerPhenotypic modulation of auto-reactive cells by insertion of tolerogenic molecules via MSC-derived exosomes.Characteristics and PD-1 expression of peripheral CD4+CD127loCD25hiFoxP3+ Treg cells in chronic HCV infected-patients.Immunity and immune suppression in human ovarian cancer.
P2860
Q24615454-B96B4CD1-18BD-429A-B55A-FCB0AFCA7857Q26765348-AAFF6095-FB64-4A28-9F54-60DC59551222Q26776126-6C3212F9-0DD8-43B3-8123-6D55AD6435FAQ27319650-6A8952AD-EE91-46CA-9217-C9D80EFBAE9FQ27490355-3D429A40-E641-4E5C-AAF4-736B0EE41D5FQ27686800-D9E0B89B-BD44-43C4-A939-C9D3AEF9A55EQ27687098-B1447584-1C50-473C-9503-985227DDBBCAQ28068959-9DAFF783-485B-4FAC-991D-5484291B491AQ28080920-CB6937DF-52A4-4F86-99DF-133FF25D3329Q28082828-25354BD2-6CA7-479C-96E3-8EF3052741D6Q30080038-9FD4AB4F-30A8-4A2C-9FAD-90B0DAACC705Q33606773-DA89C850-B7D8-4CAE-B11B-4FE959D3B128Q33631222-5E97E490-60B6-4D83-963B-5CE123F3C366Q33728298-6EEF9E54-ECCC-489D-897C-7F9AEDBF046DQ33829687-863404E7-AD90-472C-B533-E7DCF688C886Q33873566-67DFE746-EE48-4033-9770-5EEB23C88C9AQ33874652-436A63E7-65AF-43AC-BFB4-12B35073F708Q33889097-753D15BD-5D48-47DD-A37A-2FC52365501FQ33903998-5227C1FA-7275-4F6E-95FD-725DEFE216BCQ33950640-94E28B4A-A954-42E8-8386-C34F5145F0A8Q33980424-8D52B8F4-08A5-41BE-9DE2-DAB7B487078AQ34075574-91887CE5-AAAF-433F-8222-4EBA349C2FD5Q34094680-80484442-28AA-4EAA-BA3D-588ED03820F2Q34195209-C8D1F332-9208-41C1-BD42-C3D62AE5EFBEQ34210664-22BC68DF-0717-4180-97F8-067EB3794BCCQ34353081-E7BA9128-930E-4A4B-BB29-BC59B19A5616Q34427311-D5290571-574B-40EB-9F0E-8D63E53680F5Q34466498-8E00838D-6E33-4C62-917D-BE31A05EBB50Q34511652-2A7FFD48-5257-4E60-860A-3079C7982756Q34589567-BDFBA56C-0CC5-44C2-BE0C-00183948AAD8Q34606735-382343C0-C771-4566-B45F-CCDA23F6D905Q34631825-8988F0AA-F9D5-48D5-8833-EBC416B44904Q34691040-48B9CD38-E1AA-413C-857F-6F288BF98BF4Q34755205-83DB623E-9491-47E0-AD00-710D65E32E6AQ34955808-C5E2BBFC-D7D3-441C-90F6-1BAAC365301AQ34990554-AD9AB542-1F48-45FA-9C7E-0D935E686690Q35032491-9A023ACA-D0DE-4EA4-8173-6655D1F92385Q35035427-0EC36929-8AFF-4092-9577-46ABEB905045Q35085469-2172008A-6D14-47AC-9C29-489C967D5166Q35138135-0EFFDD2E-B71A-4859-AC89-203748FB780A
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
PD-1 and its ligands in T-cell immunity.
@ast
PD-1 and its ligands in T-cell immunity.
@en
type
label
PD-1 and its ligands in T-cell immunity.
@ast
PD-1 and its ligands in T-cell immunity.
@en
prefLabel
PD-1 and its ligands in T-cell immunity.
@ast
PD-1 and its ligands in T-cell immunity.
@en
P2093
P1476
PD-1 and its ligands in T-cell immunity.
@en
P2093
Arlene H Sharpe
Loise M Francisco
Mary E Keir
P304
P356
10.1016/J.COI.2007.04.012
P577
2007-04-12T00:00:00Z